162 related articles for article (PubMed ID: 38590569)
1. Effects of total saikosaponins on CYP3A4 and CYP1A2 in HepaRG cells.
Tang Y; Li H; Tang J; Hu L; Ma F; Liu Y; Tang F
Exp Ther Med; 2024 May; 27(5):217. PubMed ID: 38590569
[TBL] [Abstract][Full Text] [Related]
2. Effects of saikosaponin-d on CYP3A4 in HepaRG cell and protein-ligand docking study.
Li H; Tang Y; Wei W; Yin C; Tang F
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):661-668. PubMed ID: 33369126
[TBL] [Abstract][Full Text] [Related]
3. Effects of Saikosaponin D on CYP1A2 and CYP2D6 in HepaRG Cells.
Li H; Tang Y; Wang Y; Wei W; Yin C; Tang F
Drug Des Devel Ther; 2020; 14():5251-5258. PubMed ID: 33273809
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 1A2 Messenger RNA is a More Reliable Marker than Cytochrome P450 1A2 Activity, Phenacetin O-Deethylation, for Assessment of Induction Potential of Drug-Metabolizing Enzymes Using HepaRG Cells.
Ogasawara A; Kato N; Torimoto N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2018; 12(1):14-23. PubMed ID: 29357810
[TBL] [Abstract][Full Text] [Related]
5. Omeprazole Induces CYP3A4 mRNA Expression but Not CYP3A4 Protein Expression in HepaRG Cells.
Fujita Y; Miyake T; Shao X; Aoki Y; Hasegawa E; Doi M
Biol Pharm Bull; 2024; 47(6):1218-1223. PubMed ID: 38925922
[TBL] [Abstract][Full Text] [Related]
6. Imidazoacridinone antitumor agent C-1311 as a selective mechanism-based inactivator of human cytochrome P450 1A2 and 3A4 isoenzymes.
Potęga A; Fedejko-Kap B; Mazerska Z
Pharmacol Rep; 2016 Aug; 68(4):663-70. PubMed ID: 27110874
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of the HepaRG cell line model for drug toxicity studies using two different cultivation conditions: advantages and limitations.
Hammour MM; Othman A; Aspera-Werz R; Braun B; Weis-Klemm M; Wagner S; Nadalin S; Histing T; Ruoß M; Nüssler AK
Arch Toxicol; 2022 Sep; 96(9):2511-2521. PubMed ID: 35748891
[TBL] [Abstract][Full Text] [Related]
8. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.
Rubin K; Janefeldt A; Andersson L; Berke Z; Grime K; Andersson TB
Drug Metab Dispos; 2015 Jan; 43(1):119-25. PubMed ID: 25371393
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous assessment of cytochrome P450 activity in cultured human hepatocytes for compound-mediated induction of CYP3A4, CYP2B6, and CYP1A2.
Rhodes SP; Otten JN; Hingorani GP; Hartley DP; Franklin RB
J Pharmacol Toxicol Methods; 2011; 63(3):223-6. PubMed ID: 21111054
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail.
Berger B; Donzelli M; Maseneni S; Boess F; Roth A; Krähenbühl S; Haschke M
Front Pharmacol; 2016; 7():443. PubMed ID: 27917125
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 inhibition activities of non-standardized botanical products.
Abduraman MA; Mustafa NH; Yaacob NS; Amanah A; Tan ML
J Ethnopharmacol; 2022 Oct; 296():115406. PubMed ID: 35659627
[TBL] [Abstract][Full Text] [Related]
12. Salvianolic acid B modulates the expression of drug-metabolizing enzymes in HepG2 cells.
Wang QL; Wu Q; Tao YY; Liu CH; El-Nezami H
Hepatobiliary Pancreat Dis Int; 2011 Oct; 10(5):502-8. PubMed ID: 21947724
[TBL] [Abstract][Full Text] [Related]
13. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
15. New Screening Criteria Setting on Evaluation of Cytochrome P450 Induction Using HepaRG Cells with Multiplex Branched DNA Technologies in Early Drug Discovery.
Ogasawara A; Torimoto N; Tsuda N; Aohara F; Ohashi R; Yamada Y; Taniguchi H
Drug Metab Lett; 2016; 10(3):152-160. PubMed ID: 27550199
[TBL] [Abstract][Full Text] [Related]
16. HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans.
Kanebratt KP; Andersson TB
Drug Metab Dispos; 2008 Jan; 36(1):137-45. PubMed ID: 17954527
[TBL] [Abstract][Full Text] [Related]
17. Metamizole is a Moderate Cytochrome P450 Inducer Via the Constitutive Androstane Receptor and a Weak Inhibitor of CYP1A2.
Bachmann F; Duthaler U; Meyer Zu Schwabedissen HE; Puchkov M; Huwyler J; Haschke M; Krähenbühl S
Clin Pharmacol Ther; 2021 Jun; 109(6):1505-1516. PubMed ID: 33336382
[TBL] [Abstract][Full Text] [Related]
18. Modulatory effects of extracts of vinegar-baked Radix Bupleuri and saikosaponins on the activity of cytochrome P450 enzymes in vitro.
Yu T; Chen X; Wang Y; Zhao R; Mao S
Xenobiotica; 2014 Oct; 44(10):861-7. PubMed ID: 24779639
[TBL] [Abstract][Full Text] [Related]
19. Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2- and CYP3A4-selective Inhibitors.
Murray M; Zhang WV; Edwards RJ
Basic Clin Pharmacol Toxicol; 2018 Apr; 122(4):388-395. PubMed ID: 29155491
[TBL] [Abstract][Full Text] [Related]
20. Quantitative Evaluation of Cytochrome P450 3A4 Inhibition and Hepatotoxicity in HepaRG 3-D Spheroids.
Shin DS; Seo H; Yang JY; Joo J; Im SH; Kim SS; Kim SK; Bae MA
Int J Toxicol; 2018; 37(5):393-403. PubMed ID: 29923436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
